Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

Lignende værker

• 344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
  af: Arnulf Stenzl, et al.
  Udgivet: (2020-11-01)
• Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
  af: Brian F. Dinerman, et al.
  Udgivet: (2024-11-01)
• Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
  af: Matthew D. Tucker, et al.
  Udgivet: (2019-08-01)
• Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
  af: J.M. Piulats, et al.
  Udgivet: (2020-07-01)
• Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
  af: Harry J. Han, et al.
  Udgivet: (2020-08-01)